[EN] SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT<br/>[FR] INHIBITEURS À PETITES MOLÉCULES DE MUTANT DE KRAS G12D
申请人:MERCK SHARP & DOHME
公开号:WO2022221739A1
公开(公告)日:2022-10-20
Compounds or their pharmaceutically acceptable salts can inhibit the G12D mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
化合物或其药学上可接受的盐可以抑制Kirsten大鼠肉瘤(KRAS)蛋白的G12D突变,并预计具有治疗剂的效用,例如,用于治疗癌症。本公开还提供了包含此处披露的化合物或其药学上可接受的盐的制药组合物。本公开还涉及使用该化合物或其药学上可接受的盐在癌症治疗和预防以及为此目的制备制药的方法。